MEDIA CENTER: Press Releases

Included below are press releases that were created as of the dates listed and that reflected management’s views as of such dates.  The information contained therein should not be considered current and may not be accurate.  Karyopharm assumes no obligation to update the information in the press releases.

October 22nd 2013
Karyopharm Therapeutics Announces Oral Presentations at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) XPO1 Antagonists in preclinical models of Autoimmune Disease
Read More >

October 7th 2013
Karyopharm Therapeutics Files Registration Statement for Proposed Initial Public Offering
Read More >

October 3rd 2013
Karyopharm Therapeutics Announces Appointment of Garen Bohlin to Board of Directors
Read More >

August 7th 2013
Karyopharm Therapeutics Announces Preclinical Data for Selinexor (KPT-330) in Acute Myeloblastic Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Models at FASEB Science Research Conferences
Read More >

July 31st 2013
Karyopharm Therapeutics Secures $19 Million in Series B Financing Extension
Read More >

July 31st 2013
Karyopharm Therapeutics Initiates a Phase 1b Food-Effect Clinical Trial with the Novel Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients with Advanced Sarcomas
Read More >

June 2nd 2013
Karyopharm Therapeutics Presents Clinical Data for Selinexor (KPT-330), a First-in-Class Selective Inhibitor of Nuclear Export (SINE), in Solid Tumors at the 2013 ASCO Annual Meeting
Read More >

May 28th 2013 
Karyopharm Therapeutics to Present New Data on Selective Inhibitor of Nuclear Export (SINE), KPT-330, at 2013 EHA Congress
Read More >

May 20th 2013 
Karyopharm Therapeutics Raises $48.2 Million in Series B Financing
Read More >

May 15th 2013 
Karyopharm Therapeutics to Present Clinical Data on Selective Inhibitors of Nuclear Export (SINE), KPT-330, at 2013 ASCO Annual Meeting
Read More >

May 9th 2013
Karyopharm Therapeutics to Present Data on Selective Inhibitors of Nuclear Export (SINE) to treat Influenza and HIV at International Congress on Antiviral Research (ICAR)
Read More >

March 26th 2013 
Karyopharm Therapeutics Announces:
15 Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models at the American Association of Cancer Research (AACR) Meeting
Read More >

February 5th 2013 
Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research & Development
Read More >

January 17th 2013 
Karyopharm Therapeutics Initiates Treatment of Patients with Acute Myeloid Leukemia (AML) in Phase 1 Trial with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE)
Read More >

December 4th 2012 
Karyopharm Therapeutics Initiates a Phase IIb Efficacy Study with its Novel, Oral Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Non-Hodgkin Lymphomas (NHL)
Read More >

November 13th 2012 
Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) Meeting
Read More >

November 12th 2012 
Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
Read More >

October 31st 2012 
Karyopharm Therapeutics Recognizes the Contributions of Co-Founder Ronald DePinho, MD
Read More >

October 31st 2012 
Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer
Read More >

July 25th 2012 
Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
Read More >

May 25th 2012 
Karyopharm Therapeutics Announces Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid Tumor Models at the American Society of Clinical Oncology (ASCO) Meeting
Read More >

May 8th 2012 
Karyopharm Therapeutics Announces Appointment of Co-founder Dr. Ronald DePinho to the National Academy of Sciences
Read More >

March 15th 2012 
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Read More >

November 8th 2011 
Karyopharm Therapeutics Announces Presentations by Seven Collaborators showing Major Progress in advancing Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at American Society of Hematology (ASH) Meeting
Read More >

November 2nd 2011 
Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
Read More >

October 11th 2011 
Karyopharm and Katholieke Universiteit Leuven Sign Exclusive Collaboration for the Discovery of Novel CRM1/Exportin 1 Inhibitors
Read More >

January 6th 2011 
Multiple Myeloma Research Foundation (MMRF) Invests $3 Million in Development of Next-Generation Treatments
Read More >

January 5th 2011 
Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
Read More >

November 3rd 2010 
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Read More >

June 7th 2010 
Karyopharm Therapeutics has signed an agreement with O2h, a discovery services company, in order to further its lead small molecule program toward the nomination of a development candidate
Read More >

April 30th 2009 
The crystal structure of CRM1 in complex with a substrate called snurportin 1 was solved by our collaborator Prof. Yuh Min Chook (University of Texas Southwestern)

© 2014 Karyopharm Therapeutics

Site by Emasai

Emasai.com